Synopsis The study, also known as TOPACIO, aimed to evaluate the clinical activity and safety of combination treatment with niraparib and pembrolizumab in patients with advanced or metastatic triple-negative breast cancer. The study participants were administered oral niraparib and intravenous pembrolizumab. Following this, they were assessed for objective response rate, safety, disease control rate, duration of response, progression-free survival, and overall survival. The drug combination was found to be beneficial in the said population.
This “ Journal Watch ” discusses “ Open-label Clinical Trial of Niraparib Combined with Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer ” published in the journal JAMA Oncology, 2019. Authors - Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. What was the need for the study? Previous research…
